

## SUPPLEMENTARY DATA

### **Funding Sources:**

BARI 2D is funded by the National Heart, Lung, and Blood Institute and the National Institute of Diabetes and Digestive and Kidney Diseases ( U01 HL061744, U01 HL061746, U01 HL061748, U01 HL063804). BARI 2D received significant supplemental funding provided by GlaxoSmithKline, Collegeville, Pa; Lantheus Medical Station, NJ; Abbott Laboratories Inc, Abbott Park, Ill; and Pfizer Inc, New York, NY. Generous support is given by Abbott Laboratories Ltd, MediSense Products, Mississauga, Canada; Bayer Diagnostics, Tarrytown, NY; Becton, Dickinson and Company, Franklin Lakes, NJ; J.R. Carlson Labs, Arlington Heights, Ill; Centocor Inc, Malvern, Pa; Eli Lilly and Company, Indianapolis, Ind; LipoScience Inc, Raleigh, NC; Merck Sante, Lyon, France; Novartis Pharmaceuticals Corporation, East Hanover, NJ; and Novo Nordisk, Inc Princeton, NJ. A full listing of all sponsors can be found in the Supplementary Appendix at <http://www.NEJM.org> (N Engl J Med. 2009; 360: 2503-2515). Imaging Inc (formerly Bristol-Myers Squibb Medical Imaging, Inc), North Billerica, Mass; Astellas Pharma US Inc, Deerfield, Ill; Merck & Co Inc, Whitehouse.

SUPPLEMENTARY DATA

**Supplementary Table 1.** Characteristics of Participants Excluded from DPN Analysis vs. Those Included in DPN Analysis

	Excluded (N=209)	Included (N=2159)	P-Value
Female, %	32	29	0.42
Age at study entry, years	64 ± 10	62±9	0.01
Race/Ethnicity, %			0.79
White non-Hispanic	66	66	
Black non-Hispanic	18	17	
Hispanic	12	13	
Asian	3	4	
Other	1	1	
Region			<0.0001
USA	81	62	
Canada	7	16	
Mexico	2	4	
Brazil	6	16	
Czech Republic/Austria	4	3	
Height, cm	170 ± 12	168 ±10.2	0.02
BMI, kg/m <sup>2</sup>	31 ± 7	32 ± 6	0.46
Hypertension, %	90	82	0.007
History of MI, %	35	32	0.32
Cerebrovascular accident, %	12	10	0.24
Angina at baseline			0.39
No angina	15	18	
Equivalents only	22	21	
Classic angina	64	60	
Non-coronary artery disease	26	24	0.34
Duration of DM, years	11 ± 10	10 ± 9	0.11
Peripheral pitting edema, %	21	15	0.05
Lower extremity amputation, %	0.5	1	0.38
Macro albuminuria, %	17	9	0.002
GFR (MDRD)	75± 24	79 ± 30	0.01
Current Smoker, %	16	12	0.22
Alcohol consumption beyond recommended levels, %	9	3	<0.0001
HbA1c, %	7.6 ± 1.7	7.7±1.6	0.89
HbA1c (mmol/mol)	60 ±18.7	61 ±17.6	0.89
LDL, mg/dl	93± 34	96±33	0.22
HDL, mg/dl	38 ± 12	38 ±10	0.99
Triglycerides, mg/dl	189± 172	180 ± 132	0.48
Systolic BP, mm Hg	133 ± 21	132 ± 20	0.53
Diastolic BP, mm Hg	73 ± 12	75 ± 11	0.13
Myocardial Jeopardy,%	48 ± 24	44± 24	0.03
LVEF < 50%	32	16	<0.0001
Beta Blocker At Entry, %	77	73	0.19

## SUPPLEMENTARY DATA

Calcium Channel Blocker At Entry, %	10	10	0.77
ACE/ARB At Entry, %	74	77	0.31
Aspirin At Entry, %	86	88	0.34
Statin At Entry, %	73	75	0.56
Fibrate At Entry, %	7	9	0.47
Biguanide At Entry, %	46	55	0.02
TZD At Entry, %	21	19	0.46
Sulfonylurea At Entry, %	49	54	0.21
On Insulin At Entry, %	28	28	0.88

Data is presented as mean  $\pm$  standard deviation or %.

BMI: body mass index; HbA1c: hemoglobin A1c; MI: myocardial infarction; LV: left ventricle; BP: blood pressure;

LDL: low density lipoprotein; HDL: high density lipoprotein; ACEi: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker;

TZD: thiazolidinediones.

### Supplementary Table 2. Characteristics of Participants in Per Protocol Analysis

	(N=430)	(N=971)	Value
Age at study entry, years	63 $\pm$ 9	62 $\pm$ 9	0.19
Duration of DM, years	7 $\pm$ 7	11 $\pm$ 9	<0.0001
HbA1c, %	7.0 $\pm$ 1.3	7.8 $\pm$ 1.6	<0.0001
HbA1c (mmol/mol)	53 $\pm$ 14.3	62 $\pm$ 17.6	<0.0001
On insulin at baseline, %		31	<0.0001
LDL, mg/dl	95 $\pm$ 31	98 $\pm$ 33	0.12
HDL, mg/dl	37 $\pm$ 9	39 $\pm$ 11	0.01
Systolic BP, mm Hg	31 $\pm$ 20	132 $\pm$ 20	0.38
Diastolic BP, mm Hg	76 $\pm$ 11	75 $\pm$ 11	0.07

Data is presented as mean  $\pm$  standard deviation or %.

DM: diabetes mellitus; HbA1c: hemoglobin A1c; BP: blood pressure; LDL: low density lipoprotein; HDL: high density lipoprotein